PAK1 and neoplasm: The targetability of PAK1-driven angiogenesis, not linked to VEGF or VEGF-C, was demonstrated by knockdown of involved molecules in the pro-angiogenic axis and pharmacologic inhibition of PAK1 with PF3758309 in vitro, as well as significant inhibition on MVD and tumor growth by either siCSF2 or PF3758309 in vivo.